This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Danesh FR and Kanwar YS (2004) Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 18: 805–815
Campese VM et al. (2005) Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 16 (Suppl 1): S11–S17
D'Amico G (2006) Statins and renal diseases: from primary prevention to renal replacement therapy. J Am Soc Nephrol 17 (Suppl 2): S148–S152
Navaneethan SD et al. (2006) Statins in patients with chronic kidney disease: evidence from systematic reviews and randomized clinical trials. PLoS Med 3: e123
Wanner C and Krane V (2006) Lessons learnt from the 4D trial. Nephrol Ther 2: 3–7
Kearney PM and Baigent C (2006) Statins: are any questions unanswered? Curr Opin Lipidol 17: 418–425
Acknowledgements
The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Levi, M. Do statins have a beneficial effect on the kidney?. Nat Rev Nephrol 2, 666–667 (2006). https://doi.org/10.1038/ncpneph0336
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0336
This article is cited by
-
Nuclear hormone receptors in diabetic nephropathy
Nature Reviews Nephrology (2010)